Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

Overview of attention for article published in JAMA Oncology, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 28 news outlets
blogs: 3 blogs

twitter: 89 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 119 Mendeley

So far, Altmetric has seen 113 X posts from 89 X users, with an upper bound of 345,322 followers.

@5_utr @NRGonc Isn’t that nearly the same as the various post hoc studies using a completed RCT that didn’t involve the marker (eg https://t.co/Q8bMDBvRoA)?

@ndesai2005 @GSCollins https://t.co/hMWJRIpYDS “There was not a statistically significant interaction between GC score and hormone treatment effect for DM (HR, 1.03; 95% CI, 0.82-1.30; P = .80), PCSM (HR, 1.13; 95% CI, 0.81-1.57; P = .46), or OS (HR, 0.97…

De los estudios más interesantes del año en #GUOnc

Open Access UCL Research: Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial https://t.co/EJ9AEOIYR6

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 109 additional X posts.